听觉脑干植入在肿瘤与非肿瘤患者中的结局:一项系统综述
本系统综述检索1990至2021年PubMed、Embase和Web of Science核心合集,纳入36项研究、662例肿瘤患者和267例非肿瘤患者,比较听觉脑干植入(ABI)的听觉表现。肿瘤组闭合集单词加权平均言语识别率为39.2%,非肿瘤组为79.8%;本研究创建的APROSPER量表显示非肿瘤组听觉表现优于肿瘤组(3.5 vs 3.0,P = .04)。
要点
- 肿瘤组ABI闭合集单词加权平均识别率39.2%,非肿瘤组79.8%。
- APROSPER量表评分非肿瘤组3.5优于肿瘤组3.0(P = .04)。
- 标准化听觉测试评分在肿瘤与非肿瘤患者间相似。
核心结论
- 标准化听觉测试评分在肿瘤与非肿瘤ABI患者间相似,但APROSPER量表显示非肿瘤患者ABI表现优于肿瘤患者。
研究设计与样本
- 系统综述,检索PubMed、Embase和Web of Science核心合集1990年至2021年的文献。
- 纳入已发表的、包含5例及以上儿童或成人ABI使用者的研究,共纳入36项研究进行全文审查。
- 数据提取自662例肿瘤患者和267例非肿瘤患者,其中83%为语后聋、17%为语前聋。
主要发现
- 肿瘤ABI患者研究的闭合集单词加权平均言语识别率为39.2%(范围19.6%-83.3%),开放集单词为23.4%(范围17.2%-37.5%),开放集句子为21.5%(范围2.7%-48.4%),CAP评分为3.1(范围1.0-3.2)。
- 非肿瘤ABI患者研究的闭合集单词加权平均言语识别率为79.8%(范围31.7%-84.4%),开放集句子为53.0%(范围14.6%-72.5%),CAP评分为2.30(范围2.0-4.7)。
- 平均APROSPER结果显示非肿瘤患者听觉表现优于肿瘤患者(3.5 vs 3.0,P = .04)。
- 肿瘤与非肿瘤ABI患者之间最常见副作用也存在差异。
关键数值与推荐
- APROSPER量表为本研究创建,用于比较总体表现:非肿瘤组3.5 vs 肿瘤组3.0(P = .04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To elucidate the differences in auditory performance between auditory brainstem implant (ABI) patients with tumor or nontumor etiologies. DATA SOURCES: PubMed, Embase, and Web of Science Core Collection from 1990 to 2021. REVIEW METHODS: We included published studies with 5 or more pediatric or adult ABI users. Auditory outcomes and side effects were analyzed with weighted means for closed-set, open-set speech, and categories of auditory performance (CAP) scores. Overall performance was compared using an Adult Pediatric Ranked Order Speech Perception (APROSPER) scale created for this study. RESULTS: Thirty-six studies were included and underwent full-text review. Data were extracted for 662 tumor and 267 nontumor patients. 83% were postlingually deafened and 17% were prelingually deafened. Studies that included tumor ABI patients had a weighted mean speech recognition of 39.2% (range: 19.6%-83.3%) for closed-set words, 23.4% (range: 17.2%-37.5%) for open-set words, 21.5% (range: 2.7%-48.4%) for open-set sentences, and 3.1 (range: 1.0-3.2) for CAP scores. Studies including nontumor ABI patients had a weighted mean speech recognition of 79.8% (range: 31.7%-84.4%) for closed-set words, 53.0% (range: 14.6%-72.5%) for open-set sentences, and 2.30 (range: 2.0-4.7) for CAP scores. Mean APROSPER results indicate better auditory performance among nontumor versus tumor patients (3.5 vs 3.0, P = .04). Differences in most common side effects were also observed between tumor and nontumor ABI patients. CONCLUSION: Auditory performance is similar for tumor and nontumor patients for standardized auditory test scores. However, the APROSPER scale demonstrates better ABI performance for nontumor compared to tumor patients.
引用
- Garcia A, Haleem A, Poe S, et al. Auditory Brainstem Implant Outcomes in Tumor and Nontumor Patients: A Systematic Review. Otolaryngol Head Neck Surg. 2024. PMID: 38329219. doi:10.1002/ohn.662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。